Commercial Agreements, Stock Price Updates, Regulatory Approvals, Patent Litigation Settlements, and New Health Plan Strategies

   Commercial Agreements, Stock Price Updates, Regulatory Approvals, Patent
 Litigation Settlements, and New Health Plan Strategies - Research Report on
               Biogen, Express Scripts, GSK, Actavis, and Aetna

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, December 23, 2013

NEW YORK, December 23, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Biogen
Idec Inc. (NASDAQ: BIIB), Express Scripts Inc. (NASDAQ: ESRX), GlaxoSmithKline
plc (NYSE: GSK), Actavis plc (NYSE: ACT), and Aetna Inc. (NYSE: AET). Today's
readers may access these reports free of charge - including full price
targets, industry analysis and analyst ratings - via the links below.

Biogen Idec Inc. Research Report

On December 17, 2013, Biogen Idec Inc. (Biogen) and Samsung Bioepis jointly
announced an agreement to commercialize anti-TNF biosimilar product candidates
in Europe, that include biosimilars for commonly used therapies to help treat
conditions like rheumatoid arthritis and Crohn's disease. Tony Kingsley,
Executive Vice President of Global Commercial Operations for Biogen,
commented, "This is a unique opportunity for us to leverage our experience in
developing and manufacturing high-quality biologics in therapeutic areas where
we are deeply focused, and provide medicines to patients where there is a
significant societal need." Kingsley added, "As a company that aims to make a
difference in the lives of patients with serious diseases, we are excited by
the potential to offer additional highly effective therapies in critical areas
where there is growing demand." The Full Research Report on Biogen Idec Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/b95b_BIIB

--

Express Scripts Inc. Research Report

On December 18, 2013, Express Scripts Inc.'s (Express Scripts) stock increased
1.63%, ending the day's session at $67.98. Over the previous three trading
sessions, shares of Express Scripts increased 2.04%, compared to the Nasdaq
Composite Index, which increased 1.73% during the same period. The Full
Research Report on Express Scripts Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.AnalystsCorner.com/r/full_research_report/91a7_ESRX

--

GlaxoSmithKline plc Research Report

On December 18, 2013, GlaxoSmithKline plc (GSK) and Theravance, Inc.
(Theravance) jointly announced that the US Food and Drug Administration (FDA)
has approved ANORO ELLIPTA as a combination anticholinergic/long-acting
beta2-adrenergic agonist (LABA) indicated for the long-term, once-daily,
maintenance treatment of airflow obstruction in patients with chronic
obstructive pulmonary disease (COPD), including chronic bronchitis and/or
emphysema. Darrell Baker, Senior Vice President and Head, GSK Global
Respiratory Franchise, said, "We believe Anoro Ellipta will be an important
treatment option for appropriate patients with COPD. It is the first
combination product approved in the US that delivers two once-daily
bronchodilators in a single inhaler. This approval is a significant
achievement for GSK." Rick E Winningham, CEO of Theravance, added, "This is a
significant milestone for Theravance and GSK and is testament to our ongoing
partnership and shared commitment to the development of respiratory
medicines." The Full Research Report on GlaxoSmithKline plc - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/2a35_GSK

--

Actavis plc Research Report

On December 11, 2013, Actavis plc (Actavis) reported that its subsidiary,
Warner Chilcott Company, LLC (Warner Chilcott), has signed into an agreement
in principle with Zydus Pharmaceuticals USA Inc. (Zydus) and Cadila Healthcare
Limited (Cadila) to settle all outstanding patent litigation related to Zydus'
generic version of Asacol HD (mesalamine) delayed-release tablets. The Company
said that in accordance with the terms of the agreement in principle, Warner
Chilcott will grant Zydus a royalty-bearing license to market its generic
Asacol HD beginning on November 15, 2015 or earlier under certain
circumstances, after the receipt of final approval by Zydus from the US Food
and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA)
for generic Asacol HD. Additionally, Actavis stated that if Zydus is not
granted FDA approval for its generic Asacol HD by July 1, 2016, Zydus will be
allowed to launch an authorized generic version of Actavis' product beginning
on July 1, 2016. The Full Research Report on Actavis plc - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/4997_ACT

--

Aetna Inc.Research Report

On December 12, 2013, Aetna Inc. (Aetna) announced a new strategy to help
employers and their employees achieve the full value of a consumer directed
health plan (CDHP). Aetna reported that its strategy, CDHP Accelerator unites
CDHPs with voluntary products, and gives greater financial protection after
the member reaches certain limits on their high-deductible health plan. Jeff
Brown, Head of Aetna Voluntary Plans, said, "We have seen that greater CDHP
participation leads to greater employee engagement, which can lead to better
health outcomes as well as cost savings for both employers and employees."
Brown added, "With the right combination of voluntary benefits we can make the
transition easier for consumers." The Full Research Report on Aetna Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/cbe9_AET

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.